Hologic is preparing for its Q3 2025 earnings report, with analysts anticipating growth in earnings per share (EPS).
Hologic, Inc. (HOLX), a prominent manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products specifically targeted at women’s health, is preparing to release its fiscal third-quarter results for the year 2025. The company, headquartered in Marlborough, Massachusetts, has established itself as a key player in the global market, focusing intensely on early detection and effective treatment solutions for a range of women’s health concerns. With a current market capitalization reaching $14.4 billion, Hologic operates through four distinct business segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, reflecting a broad approach to addressing the diverse needs within this sector. These segments allow the company to cater to various critical areas within women’s healthcare. Investors and analysts are keenly anticipating the results, particularly in light of recent performance and forward-looking projections.
Q3 2025 Expectations and Recent Performance
Ahead of the Wednesday, July 30th market close announcement, analysts are projecting Hologic to report an adjusted earnings per share (EPS) of $1.05 for the current fiscal quarter. This figure represents a slight decrease from the $1.06 reported in the comparable year-ago quarter. Importantly, the company has demonstrated a strong track record of exceeding Wall Street’s bottom-line expectations in three of the last four reporting periods, indicating a consistent ability to deliver beyond market expectations. This resilience has been a notable factor in maintaining investor confidence. However, in one previous quarter, the company fell slightly short of these estimates, highlighting the importance of continued monitoring and assessment of its operational performance.
Full-Year 2025 Projections and Growth Outlook
Looking beyond the immediate Q3 results, analysts have established a more comprehensive view of Hologic’s performance for the entire fiscal year 2025. The consensus expectation is for an adjusted EPS of $4.19, signifying a 2.7% increase compared to the $4.08 reported in fiscal 2024. This indicates a sustained growth trajectory, driven primarily by the ongoing demand for Hologic’s diagnostic and surgical products within the women’s health market. Furthermore, forward-looking projections extend into fiscal 2026, where analysts anticipate an even greater increase in adjusted EPS, forecasting a 7.4% year-over-year rise to $4.50. This suggests continued momentum and a strong strategic position for the company within the evolving healthcare landscape.
Stock Performance and Market Sentiment
Over the past 52 weeks, Hologic’s stock performance has lagged behind broader market trends. HOLX has experienced a decline of 16.8%, which is lower compared to the S&P 500 Index’s (SPX) 11.6% gain and the Health Care Select Sector SPDR Fund’s (XLV) 8.6% decline. This underperformance reflects investor sentiment, highlighting a potential undervaluation or concerns regarding the company’s short-term trajectory. However, the overall “Moderate Buy” rating among 19 analysts covering the stock, with six recommending “Strong Buy,” one suggesting a “Moderate Buy,” and 12 advising “Hold,” indicates a positive long-term outlook. The mean price target of $68.67 suggests a noteworthy 6.3% potential upside from Hologic’s current stock price levels.
Recent Results and Analyst Commentary
On May 1st, Hologic’s stock experienced a decline of 1.6% following the release of its Q2 2025 results. The primary driver of this decline was a 1.2% year-over-year decrease in revenue, largely attributed to a reduction in breast health revenue stemming from lower sales of mammography capital equipment. Despite this revenue dip, the company still managed to report an adjusted EPS of $1.03, marginally exceeding the consensus estimates. Analysts remain cautiously optimistic, viewing this as a temporary setback rather than a fundamental shift in the company’s strategic direction. The ongoing assessment of Hologic’s position within the women’s health market remains a key focus for investors and industry observers.
